Stratrix

Company profile

SEC EDGAR ↗
Industry
Pharmaceutical Preparations
Listed
NYSE: AZN
Incorporated
United Kingdom
Headquarters
Cambridge
Fiscal year end
Dec 31

Financials

FY2025
Revenue
$58.7B
Net income
$10.2B
Total assets
$114.1B
AstraZeneca — reported revenue, net income and total assets by fiscal year, from SEC filings
Fiscal yearRevenueNet incomeTotal assets
FY2025$58.7B$10.2B$114.1B
FY2024$54.1B$7.04B$104.0B
FY2023$45.8B$5.96B$101.1B
FY2022$44.4B$3.29B$96.5B
FY2021$37.4B$115.0M$105.4B
FY2020$26.6B$3.14B$66.7B

Reported fiscal years from SEC filings (20-F) — SEC EDGAR ↗. Stratrix is a strategy publication, not a real-time financial data service.

Company data sheetAstraZeneca: ahead of almost everyone like it.What its filings, its peers and its economy say →

Decisions on record

One verified Decision Case on AstraZeneca, and the casebook each one belongs to.

Fork dateDecision typeWhat AstraZeneca choseWhere it stoodThe storyCasebook
2014The TurnaroundReject and stay independentTotal Revenue of $54.1 billion in 2024, up 18% (2024)Read the story →The Turnaround Casebook →
Run one of these yourself

The decisions AstraZeneca faced, as kits you can run.

Each pack takes one of these decisions and gives you the framework, a deck for the room, a model that resolves to one number, and the sourced cases behind it. $499, one-time.

The analyses

Tools to try

More from Stratrix

The Business Model Wizard

Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.

Free · about twelve minutesBuild your Model Thesis →

Stratrix Team

Every Casebook, three Strategy Packs a seat each year and Ask Stratrix, for teams that face these decisions all year.

$1,999 a year · $499 a seatWhat is included →

New analyses, by email

The defining moves in business, and what they teach, as they publish.

We'll email you a link to confirm. Unsubscribe anytime. Privacy policy.